Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.

PubWeight™: 1.57‹?› | Rank: Top 4%

🔗 View Article (PMID 25057883)

Published in J Clin Endocrinol Metab on July 24, 2014

Authors

Mehmet Kanbay1, Dimitrie Siriopol, Mutlu Saglam, Yasemin Gulcan Kurt, Mahmut Gok, Hakki Cetinkaya, Murat Karaman, Hilmi Umut Unal, Yusuf Oguz, Sebahattin Sari, Tayfun Eyileten, David Goldsmith, Abdulgaffar Vural, Gabriel Veisa, Adrian Covic, Mahmut Ilker Yilmaz

Author Affiliations

1: Department of Medicine, Division of Nephrology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey 34000; Department of Nephrology (D.S., G.V., A.C.), Gr. T.Popa University of Medicine and Pharmacy, Iasi, Romania 700115; Departments of Radiology (M.S, S.S.), Biochemistry (Y.G.K.), and Nephrology (M.G., H.C., M.I.Y., H.U.U., Y.O., T.E., A.V.), Gülhane School of Medicine, Ankara, Turkey 06018; Department of Nephrology (D.G.), Guy's Hospital, King's Health Partners, London, United Kingdom SE1 7EH, and Department of Medicine (M.K.), Division of Nephrology University School of Medicine, Instanbul, Turkey 34450.

Articles citing this

Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int (2015) 0.89

From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (2015) 0.89

Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int (2015) 0.87

The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids Health Dis (2015) 0.83

Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients. BMC Nephrol (2016) 0.79

Biomarkers: Sclerostin levels linked to CKD outcomes. Nat Rev Endocrinol (2014) 0.79

Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J (2015) 0.77

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. J Osteoporos (2016) 0.76

Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. Biomed Res Int (2017) 0.75

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism. BMC Nephrol (2016) 0.75

Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS One (2017) 0.75

Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study. Int Urol Nephrol (2017) 0.75

Articles by these authors

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol (2007) 3.06

Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42

Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant (2008) 2.41

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24

Management of atrial fibrillation in chronic kidney disease: double trouble. Am Heart J (2013) 2.14

Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. Int Urol Nephrol (2012) 2.12

The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis (2006) 2.01

A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94

Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant (2007) 1.91

Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90

Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant (2013) 1.88

FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int (2010) 1.81

Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol (2011) 1.77

Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant (2006) 1.74

Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72

The accuracy of home glucose meters in hypoglycemia. Diabetes Technol Ther (2010) 1.68

Unusual features in a patient with neurofibromatosis type 1: multiple subcutaneous lipomas, a juvenile polyp in ascending colon, congenital intrahepatic portosystemic venous shunt, and horseshoe kidney. Am J Med Genet A (2004) 1.67

Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65

Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant (2010) 1.65

Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrol Dial Transplant (2013) 1.62

Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis (2004) 1.60

Prostate cancer and adiponectin. Urology (2005) 1.59

Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis (2011) 1.55

Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant (2006) 1.53

Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif (2007) 1.51

Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant (2011) 1.50

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant (2011) 1.46

Negative outcome studies in end-stage renal disease: how dark are the storm clouds? Nephrol Dial Transplant (2007) 1.44

Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future. Nephrol Dial Transplant (2010) 1.40

Urinary nerve growth factor correlates with the severity of urgency and pain: methodological evaluation. Int Urogynecol J (2015) 1.40

A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol (2011) 1.40

Accelerating statistical research in drug safety. Pharmacoepidemiol Drug Saf (2006) 1.39

The protein science of biosimilars. Nephrol Dial Transplant (2006) 1.36

Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int (2013) 1.35

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant (2010) 1.34

Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg (2004) 1.33

Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes. J Am Soc Nephrol (2005) 1.31

Renal dysfunction may predict new onset heart failure. Am Heart J (2013) 1.28

Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant (2013) 1.28

Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol (2008) 1.27

Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.22

Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract (2006) 1.21

Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis (2003) 1.19

Pulmonary hypertension in CKD. Am J Kidney Dis (2012) 1.19

Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif (2009) 1.19

Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol (2008) 1.16

Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. Nephrol Dial Transplant (2006) 1.16

Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant (2010) 1.11

Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrol Dial Transplant (2008) 1.11

Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.10

Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif (2009) 1.10

Could salivary cortisol predict preterm delivery? A biochemical evaluation. Am J Hum Biol (2014) 1.10

Cell-free circulating DNA as a novel biomarker in patients with the acute coronary syndrome. Cardiology (2013) 1.09

Letter to the editor: re: Saliva and serum levels of pentraxin-3 and interleukin-1β in generalized aggressive or chronic periodontitis. Gümüş P, Nizam N, Nalbantsoy A, Özçaka Ö, Buduneli N. (J Periodontol 2014;85:e40-e46.). J Periodontol (2015) 1.09

Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol (2012) 1.09

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.09

Indicators of mitochondrial disease. Sao Paulo Med J (2013) 1.08

A potential biomarker for objective diagnosis of overactive bladder: urinary nerve growth factor. Int Urol Nephrol (2014) 1.08

Neutrophil-to-lymphocyte ratio may predict contrast-induced nephropathy. Angiology (2013) 1.08

ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol (2008) 1.08

Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol (2010) 1.07